Finance

Beta
Lists
002620:KRX
Jeil Pharma Holdings Inc
₩7,150.00
+0.70%
(+50.00) 1D
Jun 12, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 002620...
Open
₩7,100
High
₩7,170
Low
₩7,070
Mkt. cap
114.21B
Avg. vol.
12.74K
Volume
0.00
Dividend
0.98%
Quarterly dividend
₩17
Ex-dividend date
Dec 27, 2023
P/E ratio
8.17
52-wk high
₩9,920
52-wk low
₩6,860
EPS
₩876
Shares outstanding
15.97M
No. of employees
947
Open
₩7,100
High
₩7,170
Low
₩7,070
Mkt. cap
114.21B
Avg. vol.
12.74K
Volume
0.00
Dividend
0.98%
Quarterly dividend
₩17
Ex-dividend date
Dec 27, 2023
P/E ratio
8.17
52-wk high
₩9,920
52-wk low
₩6,860
EPS
₩876
Shares outstanding
15.97M
No. of employees
947
News stories
From sources across the web
About Jeil Pharma Holdings Inc
CEOSung Suk-je
Employees947
FoundedMar 7, 1959
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
137.63B
161.36B
154.43B
130.30B
Cost of goods sold
84.25B
93.26B
90.52B
76.95B
Cost of revenue
84.25B
80.21B
90.52B
76.95B
Research and development expenses
11.40B
9.59B
14.45B
13.89B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
43.03B
34.81B
37.01B
38.70B
Operating expense
48.64B
49.92B
57.21B
52.83B
Total operating expenses
132.89B
143.17B
147.73B
129.78B
Operating income
4.73B
9.92B
684.04M
3.66B
Other non operating income
242.80M
35.39M
-137.59M
12.25M
EBT including unusual items
3.67B
17.71B
8.80B
3.23B
EBT excluding unusual items
3.34B
18.76B
1.01B
1.79B
Income tax expense
509.80M
1.84B
-1.23B
8.63M
Effective tax rate
17.25%
24.39%
-10.51%
0.27%
Other operating expenses
135.59M
142.65M
145.52M
183.01M
Net income
1.46B
10.28B
7.36B
-309.81M
Net profit margin
0.91%
7.63%
5.59%
-0.24%
Earnings per share
-
-
-
-
Interest and investment income
366.65M
449.05M
428.19M
553.40M
Interest expense
-1.14B
-1.82B
-1.78B
-1.21B
Net interest expenses
-771.95M
-1.38B
-1.26B
-741.62M
Depreciation and amortization charges
-
-
-
-
EBITDA
7.69B
22.00B
3.82B
7.05B
Gain or loss from assets sale
119.00K
-9.00M
-
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more